For those following the drug pricing deals, the WH fact sheet about Regeneron includes a limitation not present in the fact sheets about other deals: that Medicaid will get MFN prices on "new" products. Assuming this addition is intentional, what does it mean? www.whitehouse.gov/fact-sheets/... 1/2
